SANOFI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.54 USD | -0.94% |
|
-0.27% | -2.39% |
| 05-24 | Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi | MT |
| 05-24 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 727B | ||||||
| 599B | ||||||
| 354B | ||||||
| 328B | ||||||
| 277B |
- Stock Market
- Equities
- SAN Stock
- SNY Stock
- Charts Sanofi
- Sector Chart
